ClinicalTrials.gg
CompletedNCT05769608Updated Jan 20, 2026

A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects With Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen

A Phase 2 interventional study of Placebo and lorundrostat Dose 1 in Hypertension, sponsored by Mineralys Therapeutics Inc.. Completed at 104 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Mineralys Therapeutics Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 10 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jan 2026.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
285
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,031 studies in Hypertension with a site in United States — 272 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.

Enrollment
510th of 1,779
285 · median 100
Started
2023
with 100 others
Phase 2
170 of 2,031
21 open now
Registered
1,660th of 2,031
by date

Among the 2,031 studies in Hypertension with a site in United States, this one is the 510th largest by enrollment of the 1,779 interventional ones that give a count, is one of 101 that started in 2023, is one of 170 in phase 2, and was the 1,660th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

272 of the 2,031 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:

267 more — sign in →

All 272 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,031 studies in Hypertension with a site in United States, or all of them as a file.
02

Study summary

A Phase 2 trial to evaluate the blood pressure-lowering effect of lorundrostat an aldosterone synthase inhibitor (ASI), administered as an add-on to a standardized anti-hypertensive (AHT) medication regimen, in subjects with hypertension.

Read the detailed description

This study is a Phase 2 trial to evaluate the blood pressure-lowering effects of lorundrostat (an ASI), administered as add-on to a standardized anti-hypertensive (AHT) medication regimen, in subjects with hypertension.

The study consists of a standardized AHT regimen run-in period followed by a randomized, double-blind, placebo-controlled, parallel arm period. Following the double-blind period subjects may be offered the opportunity to participate in an open-label extension (OLE) study. Subjects electing to not participate in the OLE will undergo an end of study (EoS) visit approximately 2 weeks after the last dose of study drug to complete their participation in the study.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Blood pressure
  • Uncontrolled hypertension
  • Hypertension
  • Hypertensive
  • Resistant hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. At least 18 years of age at the time of signing the form
  2. At Screening: AOBP SBP of 140-180 mmHg and AOBP DBP of 65-110 mmHg, or AOBP DBP of 90-110 mmHg
  3. 24-hour average ABPM SBP of 130-180 mmHg or 24-hour average ABPM DBP >80 mmHg
  4. Taking between 2 and 5 AHT medications, inclusive, at Screening visit.
  5. of 18-40 kg/m2 inclusive at Screening

Exclusion criteria

Exclusion Criteria:

  1. \<45 mL/min/1.73 m2 at Screening, calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula
  2. Serum potassium >5.0 mmol/L at Screening or >4.8 mmol/L at Randomization
  3. Serum sodium \<135 mmol/L at Screening
  4. History of heart failure, myocardial infarction, stroke, or within 6 months prior to Screening.
  5. Diabetes mellitus with a glycosylated () >9% (>74.9 mmol/mol) at Screening
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
285 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo once daily for 12 weeks

    Drug: Placebo

  • Experimental
    Dose 1

    lorundrostat Dose 1 once daily for 12 weeks

    Drug: lorundrostat Dose 1

  • Experimental
    Dose 2

    lorundrostat Dose 1 once daily for 4 weeks then lorundrostat Dose 2 once daily for 8 weeks

    Drug: lorundrostat Dose 2

Interventions

  • DrugPlacebo

    Placebo once daily for 12 weeks

  • Druglorundrostat Dose 1

    lorundrostat Dose 1 once daily for 12 weeks

  • Druglorundrostat Dose 2

    lorundrostat Dose 1 once daily for 4 weeks then lorundrostat Dose 2 once daily for 8 weeks for subjects who meet prespecified criteria

06

What researchers measure

Primary outcomes

  1. Change in 24-hour average ambulatory blood pressure monitoring (ABPM) systolic blood pressure (SBP)

    Time frame: Baseline (Randomization) to Week 12

Secondary outcomes

  1. Change from baseline in 24-hour average ABPM SBP at Week 4 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo

    Time frame: Baseline to Week 4

  2. Proportion of subjects with 24-hour average ABPM SBP <125 mmHg at Week 4 in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo

    Time frame: at Week 4

  3. Change from baseline in 24-hour average ABPM SBP at Week 4 by obesity status in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo

    Time frame: Baseline to Week 4

  4. Change from baseline in automated office BP (AOBP) SBP at Week 12 in subjects who were escalated to lorundrostat 100 mg QD at Week 4 (within-subjects analysis)

    Time frame: Baseline to Week 12

  5. Change from baseline in 24-hour average ABPM SBP at Week 4, by number of AHT medications in the standardized AHT regimen (2 and 3) in subjects randomized to lorundrostat 50 mg QD compared to subjects randomized to placebo

    Time frame: Baseline to Week 4

  6. Proportion of subjects with 24-hour average ABPM SBP <125 mmHg at Week 12 in subjects randomized to lorundrostat (by arm and pooled dosages) compared to subjects randomized to placebo

    Time frame: Baseline to Week 12

  7. Change from baseline in 24-hour average ABPM SBP at Week 12 by obesity status in subjects randomized to lorundrostat (by arm and pooled dosages) compared to subjects randomized to placebo

    Time frame: Baseline to Week 12

  8. Change from baseline in daytime average ABPM SBP at Week 4 and Week 12 in subjects randomized to lorundrostat 50 mg (Week 4) and by arm and pooled dosages (Week 12) compared to subjects randomized to placebo

    Time frame: Baseline to Week 4 and Week 12

  9. Change from baseline in AOBP SBP at Week 4 and Week 12 in subjects randomized to lorundrostat 50 mg QD (Week 4) and by arm and pooled dosages (Week 12) compared to subjects randomized to placebo

    Time frame: Baseline to Week 4 and Week 12

  10. Change from baseline in nighttime average ABPM SBP at Week 4 and Week 12 in subjects randomized to lorundrostat 50 mg QD (Week 4) and by arm and pooled dosages (Week 12) compared to subjects randomized to placebo

    Time frame: Baseline to Week 4 and Week 12

  11. Change from baseline in 24-hour average ABPM SBP at Week 12, in subjects randomized to lorundrostat (pooled dosages) compared to subjects randomized to placebo

    Time frame: Baseline to Week 12

07

Study locations

104 sites
  • Cardiology, P.C. - Birmingham
    Birmingham, Alabama 35211, United States
  • University of Alabama at Birmingham (UAB) - Vascular Biology and Hypertension Program
    Birmingham, Alabama 35294, United States
  • Chandler Clinical Trials
    Chandler, Arizona 85224, United States
  • Brown Road Family Medicine
    Mesa, Arizona 85213, United States
  • Scottsdale Clinical Trials (Elite Clinical Network)
    Scottsdale, Arizona 85260, United States
  • Fiel Family & Sports Medicine
    Tempe, Arizona 85383, United States
  • Noble Clinical Research
    Tucson, Arizona 85704, United States
  • Del Sol Research Management, LLC
    Tucson, Arizona 85715, United States
  • The Medical Research Group Inc.
    Fresno, California 93720, United States
  • Marvel Clinical Research
    Huntington Beach, California 92647, United States
  • University of California San Diego (UCSD) - Altman Clinical and Translational Research Institute (ACTRI)
    La Jolla, California 92037, United States
  • Clinical Trials Research
    Lincoln, California 95648, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Catalina Research Institute
    Montclair, California 91763, United States
  • Northridge Clinical Trials
    Northridge, California 91325, United States
  • University of California Irvine Medical Center
    Orange, California 92868, United States
  • Triwest Research Associates
    San Diego, California 92108, United States
  • San Jose Clinical Trials
    San Jose, California 95117, United States
  • Blue Coast Research Center
    Vista, California 92081, United States
  • Accelerated Enrollment Solutions (AES)- Vista
    Vista, California 92083, United States
  • Delta Waves, Inc.
    Colorado Springs, Colorado 80918, United States
  • CMR of Greater New Haven
    Hamden, Connecticut 06517, United States
  • Indago Research & Health Center, Inc.
    Hialeah, Florida 33012, United States
  • Clinical Neuroscience Solutions, Inc (Jacksonville)
    Jacksonville, Florida 32256, United States
  • Reserka, LLC
    Miami, Florida 33176, United States
  • Nuovida Research Center Corp
    Miami, Florida 33186, United States
  • Clinical Neuroscience Solutions, INC.
    Orlando, Florida 32801, United States
  • Patron Medical - Andres Patron D.O. (Patron Ventures, LLC)
    Pembroke, Florida 33026, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • Clinical Research of West Florida, Inc.
    Tampa, Florida 33606, United States
  • The Pierone Research Institute (Elligo Health Research)
    Vero Beach, Florida 32960, United States
  • Nephrology Associates, PC - Downtown Augusta
    Augusta, Georgia 30901, United States
  • Accel Research Sites
    Decatur, Georgia 30030, United States
  • Georgia Clinical Research, LLC
    Lawrenceville, Georgia 30044, United States
  • Randomize Now
    Peachtree City, Georgia 30269, United States
  • Alta Pharmaceutical Research Center
    Peachtree Corners, Georgia 30092, United States
  • Fellows Research Alliance, Inc
    Savannah, Georgia 31406, United States
  • Eagle Clinical Research
    Chicago, Illinois 60621, United States
  • The University of Chicago Medicine
    Chicago, Illinois 60637, United States
  • GenHarp Clinical Solutions
    Evergreen Park, Illinois 60805, United States
  • Southern Illinois School of Medicine
    Springfield, Illinois 62702, United States
  • Franciscan Physician Network-Indiana Heart Physicians
    Indianapolis, Indiana 46237, United States
  • Indiana Clinical Research
    Merrillville, Indiana 46410, United States
  • The Research Group of Lexington, LLC
    Lexington, Kentucky 40503, United States
  • Advanced Internal Medicine, PLLC (Elligo Health Research)
    Paducah, Kentucky 42001, United States
  • Versailles Family Medicine
    Versailles, Kentucky 40383, United States
  • Cambridge Clinical Trials
    Alexandria, Louisiana 71301, United States
  • Pennington Biomedical Research Center
    Baton Rouge, Louisiana 70808, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • ActivMed Practices & Research, LLC
    Methuen, Massachusetts 01844, United States
  • Saint Louis University
    St Louis, Missouri 63104, United States
  • Quality Clinical Research Inc. (QCR) - Omaha
    Omaha, Nebraska 68114, United States
  • Henderson Clinical Trials
    Henderson, Nevada 89052, United States
  • Las Vegas Clinical Trials
    Las Vegas, Nevada 89030, United States
  • Oasis Clinical Trials
    Las Vegas, Nevada 89121, United States
  • Renown Regional Medical Center
    Reno, Nevada 89502, United States
  • Seacoast Kidney & Hypertension Specialist
    Portsmouth, New Hampshire 03801, United States
  • Albany Medical College Div of Community Endocrinology
    Albany, New York 12203, United States
  • University of Buffalo
    Buffalo, New York 14215, United States
  • Columbia University
    New York, New York 10032, United States
  • Marian David, MD, PC (Elligo Health Research)
    New York, New York 11415, United States
  • Triad Internal Medicine
    Asheboro, North Carolina 27205, United States
  • Asheville Clinical Trials (Elite Clinical Network)
    Asheville, North Carolina 28803, United States
  • Duke University Medical Center Heart Center Clinical Research Unit
    Durham, North Carolina 27710, United States
  • East Carolina University (ECU) Physicians - East Carolina Heart Institute - East Carolina University Location
    Greenville, North Carolina 27834, United States
  • Lucas Research, Inc.
    New Bern, North Carolina 28557, United States
  • Iredell Memorial Hospital, Inc (Elligo Health Research)
    Statesville, North Carolina 28677, United States
  • Lillestol Research LLC
    Fargo, North Dakota 58104, United States
  • Research Innovations (Elligo Health Research)
    Beavercreek, Ohio 45431, United States
  • Diabetes and Endocrinology Associates of Stark County, Inc.
    Canton, Ohio 44718, United States
  • Intrepid Research
    Cincinnati, Ohio 45245, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Centricity Research (Aventiv Research) - Women's Health
    Dublin, Ohio 43016, United States
  • STAT Research
    Springboro, Ohio 45066, United States
  • Williamette Valley Clincial Studies
    Eugene, Oregon 97404, United States
  • AMS Cardiology
    Horsham, Pennsylvania 19044, United States
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • Accelerated Enrollment Solutions (AES)- Anderson
    Anderson, South Carolina 29621, United States
  • WR- Notus Clinical Trials, LLC
    Charleston, South Carolina 29414, United States
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29405, United States
  • Chattanooga Medical Research
    Chattanooga, Tennessee 37404, United States
  • Lifedoc Research
    Memphis, Tennessee 38115, United States
  • Clinical Neuroscience Solutions, Inc
    Memphis, Tennessee 38119, United States
  • Vanderbilt University Medical Center (VUMC)
    Nashville, Tennessee 37232, United States
  • Elligo Health Research
    Austin, Texas 78704, United States
  • Punzi Medical Center
    Carrollton, Texas 75006, United States
  • David Turbay, MD, PLLC (Elligo Health Research)
    El Paso, Texas 79905, United States
  • Houston Methodist Research Institute
    Houston, Texas 77030, United States
  • Juno Research LLC
    Houston, Texas 77040, United States
  • Gulf Coast Clinical Research
    Houston, Texas 77070, United States
  • Medical Colleagues of Texas, LLP (Elligo Health Research)
    Katy, Texas 77450, United States
  • Synergy Groups Medical - Bissonet Site
    Katy, Texas 77494, United States
  • PRX Research - Mesquite
    Mesquite, Texas 75149, United States
  • Medical Colleagues of Texas, LLP (Elligo Health Research)
    Paris, Texas 75462, United States
  • ACRC Trials
    Plano, Texas 75024, United States
  • Clinical Investigations of Texas (CIT)
    Plano, Texas 75075, United States
  • Sun Research Institute (SRI) - San Antonio
    San Antonio, Texas 78215, United States
  • San Antonio Clinical Trials
    San Antonio, Texas 78240, United States
  • Sugar Lakes Family Practice (Elligo Health Research)
    Sugar Land, Texas 77479, United States
  • The University of Utah
    Salt Lake City, Utah 84108, United States

Showing the first 100 of 104 sites. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Laffin LJ, Kopjar B, Melgaard C, Wolski K, Ibbitson J, Bhikam S, Weir MR, Ofili EO, Mehra R, Luther JM, Cohen DL, Sarraju A, Wilkinson MJ, Flack JM, Rodman D, Nissen SE; Advance-HTN Investigators. Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension. N Engl J Med. 2025 May 8;392(18):1813-1823. doi: 10.1056/NEJMoa2501440. Epub 2025 Apr 23. PubMed 40267417 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Jan 2025, 22 months.

Of 56 industry-sponsored phase 2 interventional studies under Hypertension, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 22. This study's 22 months is above that.

Counting every sponsor, half of 110 studies reached it within 25 months; a quarter within 11 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2023
First posted
Mar 15, 2023
StartActual
Mar 13, 2023
Primary completionActual
Jan 15, 2025
CompletionActual
Jan 15, 2025
Results delay requested
Jan 13, 2026
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05769608
Lead sponsor
Mineralys Therapeutics Inc.
Responsible party
Sponsor
First posted
Mar 15, 2023
Start date
Mar 13, 2023
Primary completion
Jan 15, 2025
Completion
Jan 15, 2025
Last update
Jan 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion